NEOGENOMICS INC (NEO): Results of Operations and Financial Condition
NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a99-106302026earningsrelea.htm EX-99.1 Document Exhibit 99.1 NeoGenomics Reports Second Quarter 2026 Results Total revenue increased 11% YoY to $202 million Clinical services revenue grew 14%, with NGS revenue growth of 26% Company raises full-year 2026 revenue and adju
How this was made
The 30-second read
Why it matters
Traders can reassess near-term expectations using the quantified Q2 performance (revenue, NGS growth, adjusted EBITDA, cash from operations) and the explicit guidance ranges for FY 2026, while monitoring legal and financing overhangs (DOJ settlement, convertibles and repurchases).
Market read
A primary earnings and guidance update with quantified growth and margin improvement, plus a specific capital-structure refinancing and reimbursement evidence submission that can drive sentiment and estimate revisions.
What to watch
Convertible note refinancing and capped call terms can affect perceived dilution and credit risk; also, MolDx submission status (pending approval) may delay the full reimbursement benefit.
Background
The 8-K (Item 2.02) includes NeoGenomics Q2 2026 results and a revision to full-year 2026 guidance, alongside capital structure actions via a $316M private offering of 0.75% convertible senior notes due 2032.
Ticker impact
NeoGenomics reported Q2 2026 revenue up 11% to $202M, with NGS revenue up 26%, and raised full-year 2026 revenue and adjusted EBITDA guidance.
Near-term bias higher, with volatility possible around credit/dilution optics from the 2032 convertibles and any investor focus on the DOJ settlement.
The filing is a primary earnings and guidance update with multiple quantified positives (revenue, NGS growth, adjusted EBITDA, cash from ops) and a quantified capital-structure action (new 2032 convertibles, repurchases). The DOJ settlement is a negative overhang but is described as resolved, reducing uncertainty versus an ongoing investigation.
Market effects
Supports read-across that oncology diagnostics demand and NGS mix shift remain resilient, potentially benefiting lab-services peers with similar test mix.
Limited, as the update is company-specific and US-focused laboratory operations.
Moderate, given the UK lab presence and Medicare reimbursement evidence work (MolDx) that can influence broader reimbursement expectations.
Counterpoint
The guidance raise may already be partially anticipated; investors could focus on the still-negative net loss trajectory and the one-time nature of some GAAP items (e.g., gain on extinguishment).
Key entities
- companyNeoGenomics, Inc.
NASDAQ-listed oncology diagnostics provider reporting Q2 2026 results and revised FY 2026 guidance, plus convertible refinancing and a DOJ settlement.
- regulator/reimbursement bodyMolDx
Medicare reimbursement evidence pathway referenced via RaDaR ST submission for a new indication, pending approval.
- government agencyDepartment of Justice
Resolved a civil settlement related to a self-disclosed consulting-services matter and investigation.
